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Blood vessel growth plays a key role in regenerative medicine, both to restore blood sup-
ply to ischemic tissues and to ensure rapid vascularization of clinical-size tissue-engineered
grafts. For example, vascular endothelial growth factor (VEGF) is the master regulator of
physiological blood vessel growth and is one of the main molecular targets of therapeutic
angiogenesis approaches. However, angiogenesis is a complex process and there is a need
to develop rational therapeutic strategies based on a firm understanding of basic vascu-
lar biology principles, as evidenced by the disappointing results of initial clinical trials of
angiogenic factor delivery. In particular, the spatial localization of angiogenic signals in the
extracellular matrix (ECM) is crucial to ensure the proper assembly and maturation of new
vascular structures. Here, we discuss the therapeutic implications of matrix interactions of
angiogenic factors, with a special emphasis on VEGF, as well as provide an overview of cur-
rent approaches, based on protein and biomaterial engineering that mimic the regulatory
functions of ECM to optimize the signaling microenvironment of vascular growth factors.
Keywords: angiogenesis, growth factors, extracellular matrix, fibrin, protein engineering
THERAPEUTIC ANGIOGENESIS IN REGENERATIVE MEDICINE
Therapeutic angiogenesis aims at restoring blood flow to ischemic
tissues by the generation of new vessels. This strategy targets the
treatment of ischemic diseases, where endogenous tissue itself is
insufficiently perfused, and may improve the rapid vascularization
of tissue-engineered grafts, where in vitro-generated new tissue is
transplanted to repair tissue lost through damage or surgery.
Atherosclerotic cardiovascular disease is the most frequent
cause of death in the western world (Norgren et al., 2007; Go
et al., 2013). Despite advances in medical and surgical therapy,
coronary artery disease (CAD) and peripheral arterial disease
(PAD) still have very high mortality and morbidity. No current
treatment can stop or revert the process of atherosclerotic ves-
sel obstruction and a considerable number of patients are not
suitable candidates for surgical or catheter interventions because
of age, co-morbidities, or unfavorable vascular anatomy. Thera-
peutic angiogenesis aims at restoring the original blood flow in
ischemic tissues by delivering factors that control the formation
of new vasculature. Although the obstruction is located in the
large conductance arteries, expansion of the micro-vascular cap-
illary bed, controlled by angiogenic factors, has been shown to
induce the enlargement of upstream collateral arteries through
increased shear stress and gap junction-mediated retrograde sig-
naling along vessel walls, thereby effectively producing a biological
bypass and restoring downstream perfusion (Rissanen et al., 2005;
Pries et al., 2010; Annex, 2013). This strategy represents a very
attractive approach for all patients that are not adequately treated
by current options.
On the other hand, slow or insufficient vascularization of
tissue-engineered grafts is one of the major limiting factors toward
their clinical implementation (Scherberich et al., 2010). In fact,
while clinical-size tissue grafts can be engineered in vitro by cul-
turing autologous progenitors on suitable biomaterial scaffolds,
upon in vivo implantation the limited diffusion of oxygen and
nutrients from surrounding vascular beds allows the engraftment
and differentiation of only a thin outer layer. Therefore, in the
absence of strategies to provide active vascular ingrowth, tissue-
engineered grafts larger than a few millimeters undergo necrosis in
the core regions and fail to engraft (Johnson et al.,2007; Rouwkema
et al., 2008).
ANGIOGENESIS AND THE EXTRACELLULAR MATRIX
Angiogenesis is a complex process in which the growth of nor-
mal, stable, and functional vessels is critically dependent on the
coordinated interplay in space and time of different cell types and
growth factors (GF) (Blau and Banfi, 2001). Activated endothe-
lial cells assemble into new tubular structures (morphogenesis)
and subsequently associate with pericytes (maturation). Pericytes
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provide a variety of regulatory signals, the best characterized
of which involve the TGF-β1/TGF-R, Angiopoietin/Tie2, and
EphrinB2/EphB4 pathways, leading to endothelial quiescence and
new vessel survival independently of further angiogenic stimula-
tion (stabilization) (Figure 1). The spatial localization of angio-
genic signals in the extracellular matrix (ECM) plays a funda-
mental role in ensuring the proper completion of all steps in
vascular formation.
Vascular endothelial growth factor-A (VEGF) is the master reg-
ulator of both physiological and pathological angiogenesis and is
capable, when delivered as a single factor, to start the complex
cascade of events leading to new vascular growth (Potente et al.,
2011). VEGF exists in three major splicing isoforms, which are
composed of 120/121, 164/165, and 188/189 amino acids in mouse
and human, respectively, and differ in their affinity for ECM (Park
et al., 1993). Studies in transgenic models expressing only one
of the major VEGF isoforms showed that their specific ability to
bind ECM is critical for proper vascular morphogenesis. VEGF120,
which does not bind ECM,induces vascular networks with reduced
branching and abnormally enlarged diameters, VEGF188, which
binds ECM strongly, causes opposite defects, with ectopic branch-
ing and reduced capillary size,whereasVEGF164,which binds ECM
with intermediate affinity, is the only isoform capable of induc-
ing physiologically patterned vasculature (Ruhrberg et al., 2002).
Remarkably, the combination of VEGF120 and VEGF188 also leads
to normal angiogenesis in the absence of VEGF164, showing that
a balanced matrix-binding affinity, rather than a specific isoform,
is required for proper vascular morphogenesis (Ruhrberg et al.,
2002). The formation of microenvironmental VEGF gradients in
the tissue matrix guides new capillary sprouting. The first endothe-
lial cells activated by VEGF become specialized tip cells, which
sense the VEGF gradient by extending thin filopodial processes
and migrate toward its source (Gerhardt et al., 2003). Notch sig-
naling regulates this process, as tip cells upregulate the Notch
ligand Delta-like-4 (Dll4) and activate Notch1 in adjacent cells,
instructing them to function as stalk cells (Hellstrom et al., 2007),
which proliferate to form the main trunk of the new vessel behind
the migrating tip (Gerhardt et al., 2003). However, in conditions
of pathologically high VEGF, with impaired gradient formation,
the alternate pattern of Dll4 expression and Notch activation and
the orderly formation of tip and stalk cells are disrupted (Bentley
et al., 2008).
Pericytes are recruited to nascent vessels by platelet-
derived growth factor-BB (PDGF-BB) produced by activated
FIGURE 1 |The phases of blood vessel growth and the main signaling pathways involved: endothelial morphogenesis (A), pericyte recruitment (B),
and stabilization (C).
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endothelium. PDGF-BB also binds strongly to the ECM through a
carboxy-terminal stretch of positively charged amino acids (Ost-
man et al., 1991), forming steep gradients. PDGF-BB retention in
the matrix is an absolute requirement for proper vascular matura-
tion. In fact, deletion of the retention motif from the endogenous
Pdgfb gene, leading to free diffusion of the expressed PDGF-
BB, causes pericyte detachment from endothelium and defective
angiogenesis, with retinal deterioration and sclerosis of renal
glomeruli and proteinuria (Lindblom et al., 2003). We recently
found that co-delivery of PDGF-BB can normalize the aberrant
angiogenesis induced by high and uncontrolled levels of VEGF,
through retention of pericytes on remodeling vascular structures.
However, the two GF required co-expression at a fixed relative level
from a single bicistronic vector to ensure co-localized gradients in
the tissue, whereas the same doses from separate vectors or cell
populations were not effective (Banfi et al., 2012).
LIMITATIONS OF VEGF DELIVERY FOR THERAPEUTIC
ANGIOGENESIS
All key angiogenic GFs, including VEGF-A, FGF-2, IGF, HGF,
PDGF-BB, and TGF-β1, share the common property of binding
ECM (Martino and Hubbell, 2010), which is crucially required
for their biological function to guide vascular growth toward the
hypoxic areas. Matrix interactions of angiogenic GF have pro-
found therapeutic implications and here we will discuss how this
affects delivery strategies, with the best-studied factor, VEGF, as a
paradigm. For therapeutic purposes, two main parameters need
to be controlled in order to ensure both safety and efficacy: dose
and duration of stimulation.
Despite encouraging preclinical data and phase I clinical stud-
ies, the outcome of placebo-controlled clinical trials of VEGF gene
therapy for coronary and peripheral artery disease has been disap-
pointing and clear clinical benefit has yet to be established (Gupta
et al., 2009; Giacca and Zacchigna, 2012). Retrospective analyses
of clinical trials identified several issues that undermined their
efficacy, particularly the difficulty to deliver enough VEGF at safe
vector doses into the target tissue to generate sufficient angiogen-
esis and correct ischemia (Yla-Herttuala et al., 2004; Karvinen and
Yla-Herttuala, 2010). Elegant genetic experiments have shown that
during development exquisite control of VEGF dose is required,
as variations in its levels of expression as small as a 50% reduction
(Carmeliet et al., 1996; Ferrara et al., 1996) or a two- to three-
fold increase (Miquerol et al., 2000) are lethal. Upon delivery
of exogenous VEGF to adult tissues, increased vessel permeabil-
ity causes severe edema and loss of limb in animals (Masaki
et al., 2002; Vajanto et al., 2002). Using gene delivery systems
such as retrovirally transduced myoblasts (Carmeliet, 2000; Lee
et al., 2000), adeno- and adeno-associated viral vectors (Petters-
son et al., 2000; Sundberg et al., 2001; Karvinen et al., 2011), and
plasmid DNA (Isner et al., 1996; Schwarz et al., 2000), it was shown
that uncontrolled VEGF expression induces the growth of vascular
tumors (hemangiomas) in skeletal muscle (Springer et al., 1998),
myocardium, and other tissues.
However, we found evidence that VEGF does not have an
intrinsically steep dose–response curve in vivo, but rather that the
dose delivered must be controlled at the microenvironmental level
(Ozawa et al., 2004; Von Degenfeld et al., 2006; Misteli et al., 2010;
Melly et al., 2012; Wolff et al., 2012; Mujagic et al., 2013). In fact,
due to the ECM-binding of VEGF, different GF concentrations
remain tightly localized after secretion and a few “hotspots” of
high expression can cause angioma growth even if the total dose
is rather low. Therefore, the same total dose of VEGF can have
disparate effects, therapeutic or toxic, depending on whether it is
distributed homogeneously in the tissue or not (Banfi et al., 2005).
On the other hand, sufficient duration of VEGF expression for
at least about 4 weeks is also critical for newly induced vessels to
stabilize and persist (Dor et al., 2002; Ozawa et al., 2004; Tafuro
et al., 2009).
Therapeutic challenges for delivering angiogenic GFs include
the need to control the microenvironmental distribution of their
levels in tissue, which is inherently difficult with direct gene ther-
apy approaches, while recombinant proteins, which could over-
come this issue, have too short half-lives in vivo. Tremendous
work has been done to engineer biomaterials allowing sustained
release of angiogenic GFs. In general, the biochemical and biophys-
ical properties of natural or synthetic biomaterials are modified
to ensure passive release of embedded GFs at controllable rates.
These approaches are covered in a number of excellent reviews
(Fischbach and Mooney, 2007; Phelps and Garcia, 2009; Lee et al.,
2011; Chu and Wang, 2012). On the other hand, fundamentally
different approaches aim at functionalizing biomaterials with GF-
binding domains derived from the ECM or directly modifying
GFs to specifically bind biomaterial matrices. The next sections
will highlight these approaches aimed at controlled presentation
of angiogenic GFs in their physiological ECM-bound context to
overcome their therapeutic limitations.
ENGINEERING BIOMATERIAL MATRICES TO OPTIMIZE THE
DELIVERY OF ANGIOGENIC GROWTH FACTORS
Extracellular matrix physiologically orchestrates the activity of
angiogenic GFs, regulating their local concentration, partitioning,
bioavailability, and signaling. To recapitulate the ECM regula-
tory functions, an elegant approach is to functionalize biomaterial
matrices with specific GF-binding sites derived from the ECM
(Figure 2).
FUNCTIONALIZATION OF BIOMATERIAL MATRICES WITH GROWTH
FACTOR-BINDING SITES
Most angiogenic GFs have the ability to bind specific sites in the
ECM (Schonherr and Hausser, 2000; Schultz and Wysocki, 2009)
and they will first interact with the ECM before finding their cell-
surface receptor or co-receptor. For example, VEGF-A165, FGF-2,
and PDGF-BB possess specific interactions with heparan sulfate
proteoglycans within the ECM (Capila and Linhardt, 2002; Macri
et al., 2007). Moreover, several GF-binding sites have recently been
discovered within ECM proteins such as fibronectin (Martino
and Hubbell, 2010), fibrinogen (Martino et al., 2013), tenascin
C (De Laporte et al., 2013), and vitronectin (Upton et al., 2008).
Therefore, once bound to the ECM, angiogenic GFs are released
depending on their binding affinity and the action of proteases
that specifically cleave ECM or the ECM-binding domains of
GFs (Martino et al., 2013, 2014). Consequently, ECM releases
signaling molecules at different kinetics and from different loca-
tions, which allows a very tight spatio-temporal regulation of
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FIGURE 2 | Delivery systems for angiogenic GFs inspired by the natural GF regulatory function of the ECM.
angiogenesis (Hynes, 2009; Schultz and Wysocki, 2009). To mimic
these GF-binding features, biomaterial matrices have been mod-
ified with heparin or heparan sulfate-mimetic molecules that
sequester heparin-binding GFs and control their release (Pike et al.,
2006; Nillesen et al., 2007; Lee et al., 2011) (Figure 2). For example,
synthetic hydrogel films cross-linked with heparin and derivatives
of chondroitin sulfate have been used to successfully control the
delivery of FGF-2 in a full-thickness excisional wound model in
db/db diabetic mice and showed acceleration of vascularization
(Liu et al., 2007).
Growth factor-binding sites from ECM proteins have also been
used to control the presentation of angiogenic factors (Martino
and Hubbell, 2010; Martino et al., 2011, 2013) (Figure 2). Remark-
ably, these binding sites are often promiscuous for multiple GFs
and offer the possibility to co-deliver different GFs. For example,
fibrin(ogen) has a natural affinity for several angiogenic GFs and
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fibrin matrices have been successfully used to deliver low doses of
FGF-2 and placenta growth factor-2 (PlGF-2) for wound healing
in diabetic mice (Martino et al., 2013). Moreover, the GF-binding
domain of fibrin(ogen) has been isolated and incorporated in
a synthetic PEG-based matrix, which then could sequester GFs
similarly to natural fibrin. Interestingly, treatment of wounds in
diabetic mice with FGF-2 and PlGF-2 co-delivery through the
synthetic matrix induced similar angiogenesis as with GF delivery
through fibrin (Martino et al., 2013). Therefore, integrating ECM
GF-binding domains into biomaterial matrices allows efficient
delivery of low doses of angiogenic GFs. Alternatively, biomateri-
als were functionalized with a VEGF-binding peptide derived from
VEGF-Receptor2 to allow controlled release of VEGF (Impellitteri
et al., 2012).
OPTIMIZING THE SIGNALING MICROENVIRONMENT OF ANGIOGENIC
GROWTH FACTORS
Besides controlling GF bioavailability, the ECM also modulates
GF signaling through the interplay between GFs, ECM proteins,
cell-adhesion receptors, and GF receptors (Giancotti and Tarone,
2003; Hynes, 2009; Kim et al., 2011). For example, the bind-
ing of VEGF165 to fibronectin forms molecular complexes that
induce the formation of clusters between VEGF receptor and inte-
grins (Wijelath et al., 2006; Martino et al., 2011, 2013). Because
integrins and GF receptors share several molecules in their signal-
ing machinery, these clusters can considerably enhance signaling
(Yamada and Even-Ram, 2002; Comoglio et al., 2003; Martino
et al., 2011). Thus, depending on the composition of the ECM
surrounding GF receptors, GFs induce a more or less strong signal-
ing. This synergistic signaling between integrins and GF receptors
can be exploited to lower the dose of angiogenic GF delivered
(Figure 2). For example, a multifunctional recombinant fragment
of fibronectin has been engineered to integrate a fibrin-binding
sequence, an integrin-binding domain and a GF-binding domain.
In a chronic wound model in db/db mice, co-delivery of VEGF165
and PDGF-BB with this multifunctional fibronectin fragment was
able to induce angiogenesis at low doses, while GFs delivered with-
out the fibronectin fragment had no significant effect (Martino
et al., 2011).
ENGINEERING ANGIOGENIC GROWTH FACTORS TO
INTERACT WITH NATURAL BIOMATERIAL MATRICES AND
ENDOGENOUS ECM
Instead of modifying biomaterials to enhance their affinity for
angiogenic GFs, the factors themselves can be engineered to
increase their affinity for biomaterial matrices or for the endoge-
nous ECM present at the delivery site. As a first approach, GFs
can be covalently immobilized into a biomaterial matrix using
chemical or enzymatic reactions. A variety of chemical conju-
gation methods have been developed (Zisch et al., 2003; Phelps
et al., 2013), but a potential limitation is that angiogenic GFs may
lose their activity after coupling. To address this issue, an elegant
technique has been developed to covalently cross-link GFs into
fibrin (Ehrbar et al., 2004, 2008) or fibrin-mimetic PEG matrices
(Ehrbar et al., 2007). GFs are engineered to contain an octapeptide
sequence derived from alpha-2-plasmin inhibitor (NQEQVSPL),
which is a substrate for the transglutaminase factor XIIIa. Because
fibrin and fibrin-mimetic PEG matrices are polymerized by fac-
tor XIIIa, the engineered GFs are covalently incorporated into the
matrices during the polymerization process (Figure 2). This spe-
cific enzymatic cross-linking of GFs into fibrin was demonstrated
to be effective to deliver VEGF in various animal models (Ehrbar
et al., 2004; Traub et al., 2013; Sacchi et al., 2014). For exam-
ple, optimized delivery of fibrin-bound VEGF was therapeutically
effective both in ischemic hind limb and wound-healing mod-
els, by significantly improving angiogenesis, tissue perfusion, and
healing rate (Sacchi et al., 2014).
It should be noted that, when GFs are covalently coupled to a
biomaterial matrix, their release will depend on matrix degrada-
tion and therefore the release rate will depend on the local activity
of degrading cells and enzymes. For example, GFs linked to fibrin
are released by the action of proteases such as matrix metallopro-
teinases and plasmin. In order to control the GF release kinetics
and couple release to cellular demand, GFs can be engineered to
incorporate a protease-sensitive site between the factor sequence
and the fibrin-coupling site (Ehrbar et al., 2004; Traub et al., 2013)
(Figure 2). Moreover, to fully customize release rates, the fibrin
matrix can be further functionalized with different concentrations
of the plasmin inhibitor aprotinin, which, in balance with the local
inflammatory environment, will determine the specific functional
outcome of a specific GF concentration (Sacchi et al., 2014).
Another approach consists of engineering GFs to enhance their
affinity for a natural biomaterial matrix such as fibrin, collagen,
and endogenous ECM, without covalent coupling. Recently, it has
been demonstrated that targeting endogenous ECM can enhance
the efficacy of angiogenic GFs even when they are delivered at
low doses (Martino et al., 2014). Twenty-five GFs were screened
for their binding to six key ECM proteins, namely fibronectin,
vitronectin, tenascin C, osteopontin, fibrinogen, and collagen I.
The study revealed that PlGF-2 displays a very strong affinity
to ECM proteins, especially fibronectin, tenascin C, osteopontin,
and fibrinogen, as well as heparan sulfate through its heparin-
binding sequence (PlGF-2123–144). Using rational protein engi-
neering, PlGF-2123–144 has been incorporated into angiogenic
GFs that have clinical translation limitations, namely VEGF and
PDGF-BB, endowing them with super-affinity for ECM proteins
and heparan sulfate (Figure 2). In a wound-healing model in
diabetic mice, low doses of PlGF-2123–144-fused PDGF-BB and
VEGF led to significantly faster wound closure and to more gran-
ulation angiogenesis compared to the wild-type factors, both
topically and in fibrin. Moreover, one of the critical clinical limi-
tations of VEGF, i.e., its induction of vascular hyperpermeability,
was ameliorated through this GF engineering concept (Martino
et al., 2014). Once delivered at the target site, VEGF rapidly acti-
vates its receptor and induces a burst signaling. In contrast, the
number of receptors activated within the same period of time
is most likely much lower when delivering VEGF/PlGF-2123–144,
because the engineered GF is retained within the endogenous
ECM. This could help controlling the unwanted effect of VEGF
on vascular permeability, which is directly linked to the number
of active VEGF receptor molecules. In fact, VEGF/PlGF-2123–144
induced only 10% of vascular leakage compared to the same
dose of wild-type VEGF, but induced more angiogenesis (Martino
et al., 2014).
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FUTURE DIRECTIONS
Today, the main challenge to overcome, when designing angiogenic
therapies based on recombinant GFs, is the control of their local
delivery. Moreover, since angiogenesis involves multiple sequential
signals, the delivery of multiple GFs may be required to effi-
ciently promote angiogenesis (Borselli et al., 2010; Anderson et al.,
2014). For example, systems engineered to reproduce the sequen-
tial presentation of the factors controlling the phases of endothelial
morphogenesis and vessel maturation may promote a more phys-
iological vascularization (Richardson et al., 2001; Hao et al., 2007;
Ruvinov et al., 2011; Brudno et al., 2013).
In conclusion, understanding how GFs are presented by the
ECM during physiological blood vessel growth is critical to develop
efficient and safe GF delivery platforms. Especially, approaches
mimicking the GF regulatory function of the ECM with a relatively
simple regulatory path are expected to be particularly relevant
toward clinical translation.
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